April 9, 2025 · Form 4 insider transaction
Hurvitz Chaim bought 25,000 shares of NRx Pharmaceuticals NV at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 154 days after the transaction.
Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest on April 9, 2026, subject to continued service to the Issuer.